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Abstract
Background: Salivary gland function decreases after radiation doses of 39 Gy or higher. Currently, submandibular
glands are not routinely spared. We implemented a technique for sparing contralateral submandibular glands
(CLSM) during contralateral elective neck irradiation without compromising PTV coverage.
Methods: Volumetric modulated arc therapy (RapidArc™) plans were applied in 31 patients with stage II-IV HNC
without contralateral neck metastases, all of whom received elective treatment to contralateral nodal levels II-IV.
Group 1 consisted of 21 patients undergoing concurrent chemo-radiotherapy, with elective nodal doses of 57.75
Gy (PTVelect) and 70 Gy to tumor and pathological nodes (PTVboost) in 7 weeks. Group 2 consisted of 10 patients
treated with radiotherapy to 54.45 Gy to PTVelect and 70 Gy to PTVboost in 6 weeks. All clinical plans spared the
CLSM using individually adapted constraints. For each patient, a second plan was retrospectively generated without
CLSM constraints (’non-sparing plan’).
Results: PTV coverage was similar for both plans, with 98.7% of PTVelect and 99.2% of PTVboost receiving ≥95% of
the prescription dose. The mean CLSM dose in group 1 was 33.2 Gy for clinical plans, versus 50.6 Gy in ‘non-
sparing plans’ (p < 0.001). In group 2, mean CLSM dose was 34.4 Gy for clinical plans, and 46.8 Gy for non-sparing
plans (p = 0.002).
Conclusions: Elective radiotherapy to contralateral nodal levels II-IV using RapidArc consistently limited CLSM
doses well below 39 Gy, without compromising PTV-coverage. Future studies will reveal if this extent of dose
reduction can reduce patient symptoms.
Keywords: submandibular gland sparing, volumetric modulated arc therapy, RapidArc, head and neck cancer, dose
distribution, xerostomia
Background
Bilateral nodal irradiation is indicated in patients with
head and neck cancer who present with either locally
advanced disease, or a tumor located in the midline.
Irradiation delivered using conventional, non-intensity
modulated techniques in these patients generally leads
to a high degree of xerostomia [1]. Xerostomia is a
major cause of morbidity following radiotherapy in
patients with head and neck cancer, and arises due to
irradiation of both major and minor salivary glands [2].
It causes physical difficulties in swallowing and speaking,
altered taste, predisposes to early dental caries, and is
considered by patients to be a major cause of reduced
quality of life (QoL) [3].
The use of intensity-modulated radiotherapy (IMRT)
has allowed for reduction of doses to the parotid glands
(PG) without compromising tumor coverage, and many
authors have reported a reduction in xerostomia [4-14].
Although nearly two thirds of the stimulated saliva is
produced by the PG, submandibular (SM) glands are
largely responsible for salivary output in unstimulated
conditions [15]. Unlike the PG which produces mainly
serous secretions, SM glands produce mixed serous and
mucinous secretions, and the latter accounts for a
patient’s subjective sense of moisture. Approaches that
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reduce doses to at least one SM gland can reduce the
incidence of xerostomia [16,17]. Furthermore, there
seems to be a better correlation between the incidence
of xerostomia and the mean dose to the PGs and SM
glands taken together as one organ, than to the PGs
alone [18].
The drawbacks of conventional IMRT delivery are well
recognized, with longer delivery times decreasing patient
throughput [19], and an increase in the volume of nor-
mal tissues receiving low doses of radiation. Volumetric
modulated arc therapy called RapidArc™ was intro-
duced into clinical care in 2008 [20-23], and it uses con-
tinuous changes in the dose rate, the shape of the beam,
and speed of gantry rotation to permit faster delivery of
highly modulated IMRT plans [24]. Consequently, we
implemented treatment plans that specifically spared
both the PG and the contralateral submandibular gland
(CLSM) in patients without contralateral (CL) neck
metastases requiring bilateral neck irradiation. The pre-
sent report describes the planning and clinical charac-
teristics of 31 HNC patients treated in this manner, all
of whom also had comparative plans without CLSM.
Methods
Patient selection
Use of RapidArc at our department commenced in
2008, and we developed a constraint set aiming to spare
the CLSM gland in 2009. The present study reports on
the first 31 patients who were treated with clinical spar-
ing of the CLSM gland. All patients had stage II-IV
HNC without CL lymph node metastases (except for 1
patient who had one level IV positive node) and
received elective treatment to CL nodal levels II-IV
(Table 1).
Group 1 consisted of 21 patients who underwent con-
current chemoradiotherapy, including 14 patients with
oropharyngeal cancer, 4 larynx cancer and 3 hypophar-
ynx cancer. The majority (n = 14) received three cycles
of concurrent single-agent cisplatin 100 mg/m2. Three
patients received induction chemotherapy (taxotere- cis-
platin -5-FU) followed by weekly cis- or carboplatin, 2
patients received cisplatinum 40 mg/m2 weekly, and 2
patients were only fit to receive concurrent radiotherapy
with cetuximab. Group 2 consisted of 10 patients who
were treated using only accelerated radiotherapy (6 frac-
tions/week), and included oropharynx (n = 6), larynx (n
= 3) and hypopharynx (n = 1) cancer.
All patients were positioned in a 5 point fixation mask
(Posicast® Thermoplastics, Civco Medical Solutions).
The gross tumor volume (GTV) was delineated on a
contrast-enhanced planning CT scan acquired with 2.5-
mm slice thickness. Target volumes were defined by co-
registration of diagnostic MRI scans and/or PET scans.
The gross tumor volume (GTV) was defined as the
primary tumor and involved lymph nodes on imaging
and examination under anesthesia. The ‘boost’ clinical
target volume (CTVboost) comprised the GTV with a
margin of 0.5 cm, and was corrected for anatomical
boundaries. The ‘elective’ CTV (CTVelect) included the
CTVboost plus 0.5 cm and bilateral elective lymph nodes:
CL levels II-IV and at least IL levels II-V, and level I, VI
and/or retropharyngeal nodes in accordance with pub-
lished guidelines [25,26]. A margin of an additional 3
(upper part) to 5 (shoulder region) mm was taken to
create planning target volumes (PTVs).
Planning objectives and techniques
The objectives used for the target volumes and organs at
risk are summarized in Table 2. In group 1, dose pre-
scription was set to 57.75 Gy at 1.65 Gy/fraction to the
PTVelect and 70 Gy at 2 Gy/fraction to the PTVboost
delivered as a simultaneous integrated boost (SIB). In
group 2, patients received 54.25 Gy at 1.55 Gy/fraction
tot the PTVelect. A standard constraint set was used for
RA optimization, aiming to achieve at least. 95% of the
boost dose in 99% of the PTVboost and 95% of the elec-
tive dose in 98% of the PTVelect, while keeping the boost
and elective volumes receiving >107% of the prescribed
dose as small as possible. This constraint set is similar
to that described previously [24], except for the addition
of objectives to spare the CLSM gland. The maximum
dose specified for the spinal canal was 36-40 Gy. Priori-
ties for the PTVs, spinal cord and salivary glands were
120-130, 125 and 80 respectively. Four dose objectives
were set for both PGs and the CLSM gland, and only
those objectives were interactively adapted for each indi-
vidual patient during the first 2 to 3 levels of a 5-level
multi-resolution optimization process that aimed to
keep the mean CLSM dose low without compromising
PTV coverage. The built-in normal tissue objective with
a priority of 80, and 3 constraints on a 1 cm thick ring
created around the PTVs were used to enforce a steep
dose fall-off outside the target volumes.
Optimization and dose calculations were performed
using the Eclipse treatment planning system (version
8.2.23) in 10 patients, and subsequently Eclipse version
8.6.15 for 21 patients (Varian Medical Systems, Palo
Alto). Treatment delivery was performed using 6 MV
photon beams from a Varian 2300 linac with the Millen-
nium 120-MLC. The Anisotropic Analytical Algorithm
(AAA) photon dose calculation algorithm was used with
a calculation grid of 2.5 mm. Each plan consisted of 2
coplanar arcs of 358° (one counterclockwise (CCW), one
clockwise (CW)). In the first 10 patients, a sequential
approach was used, in which the first arc plan was used
as a base dose plan for the second arc plan which com-
pensated for possible under- or overdosage in the first
arc plan, leading to a homogeneous dose in the PTV
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[23]. In the last 21 patients, the 2 arcs were simulta-
neously optimized. To appreciate the target coverage in
the areas where the PTV approaches the surface, a local
build-up of 6 mm (to overcome dose build-up under the
skin) was used for optimization purposes.
For plan evaluation, the boost and elective volumes
receiving at least 95% of the prescribed doses (V95), as
well as the V107, were registered. This was done in the
plans using the local build-up for optimisation purposes.
A conformity index (CI), which was defined as the ratio
between the volume receiving at least 95% of the pre-
scribed boost dose and the volume of the PTVboost, was
calculated. The mean doses of both PGs, the CLSM
gland and the maximum dose to the spinal canal were
also registered.
In order to confirm the results achieved in our initial
31 patients, the CLSM doses of 25 consecutive patients
treated subsequently using the same technique, were
also analyzed. All patients had stage II-IV disease, were
treated electively to the CL levels II-IV and received a
dose of 70 Gy to the PTVboost and 54.25 Gy to the
PTVelect.
Table 1 Patient characteristics
Patient Site subsite TNM stage elective dose (Gy) chemotherapy
1 oropharynx tonsil T4N2b IV 57.75 TPF + carbo weekly
2 oropharynx base of tongue T3N0 III 57.75 CDDP 3x
3 oropharynx tonsil T3N0 III 57.75 cetuximab
4 oropharynx tonsil T2N2b IV 57.75 CDDP weekly
5 oropharynx tonsil T4bN0 IV 57.75 TPF + CDDP weekly
6 oropharynx base of tongue T3N2b IV 57.75 CDDP 3x
7 oropharynx tonsil T3N1 III 57.75 CDDP 3x
8 oropharynx tonsil T2N2b IV 57.75 CDDP 3x
9 oropharynx pharyngeal wall T3N2b IV 57.75 CDDP 3x
10 oropharynx tonsil T3N2b IV 57.75 CDDP 3x
11 oropharynx tonsil T2N2b IV 57.75 CDDP 3x
12 oropharynx base of tongue T2N1 III 57.75 CDDP 3x
13 oropharynx tonsil T4N1 IV 57.75 TPF + carbo weekly
14 oropharynx base of tongue T3N0 III 57.75 cetuximab
15 larynx supraglottis T3N1 III 57.75 CDDP weekly
16 larynx supraglottis T3N0 III 57.75 CDDP 3x
17 larynx supraglottis T4N0 IV 57.75 CDDP 3x
18 larynx supraglottis T3N0 III 57.75 CDDP 3x
19 hypopharynx postcricoid T3N2c IV 57.75 CDDP 3x
20 hypopharynx piriform sinus T4aN2b IV 57.75 CDDP 3x
21 hypopharynx piriform sinus T4N2b IV 57.75 CDDP 3x
22 oropharynx tonsil T2N0 II 54.25
23 oropharynx base of tongue T1N1 III 54.25
24 oropharynx tonsil T2N0 II 54.25
25 oropharynx base of tongue T3N0 III 54.25
26 oropharynx soft palate T2N1 III 54.25
27 oropharynx soft palate T1N0 I 54.25
28 larynx transglottis T2N2b IV 54.25
29 larynx glottis T3N0 III 54.25
30 larynx supraglottis T2N0 II 54.25
31 hypofarynx piriform sinus T2N1 III 54.25
CDDP: cisplatinum
CDDP 3x: 3 cycles of cisplatinum 100 mg/m2
TPF: docetaxel 75 mg/m2 day 1, cisplatinum 75 mg/m2day 1, 5-FU 750 mg/m2 day 1-5
Table 2 Planning objectives/constraint set
Target Volume min dose (Gy) max dose (Gy) priority
PTV elective (1.65 Gy/fr) 57 58.5 120-130
PTV elective (1.55 Gy/fr) 53.5 55 120-130
PTV boost 69 71 120-130
spinal cord 36 125
standard ring DVH 90-110
parotids DVH, adapt during first iterations 80
CLSM DVH, adapt during first iterations 80
Shoulders 20 75
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Planning study
For purposes of the present analysis, a second plan was
retrospectively generated using identical constraints on
all volumes except the CLSM gland (referred to as the
‘non-sparing plan’). Doses to the PTVs, PGs, CLSM
gland and spinal canal were registered and compared
for both plans. Volumes encompassed by the 95% iso-
dose line (V95) of the elective and boost dose were gen-
erated for the sparing and non-sparing plans and
compared by using the Wilcoxon signed-ranks test. P <
0.05 was considered as significant.
Quality assurance (QA)
Individual plan QA was performed for all patients. For
10 patients, dose distributions were measured using Gaf-
chromic® EBT films inserted in 1-3 coronal planes of a
cube polystyrene phantom, allowing dose verification
during a single treatment session [23]. In the remaining
21 patients, QA was performed using the MatriXx ioni-
zation chamber array (IBA, Louvain-la-Neuve, Belgium)
in one coronal plane of an in-house designed polystyr-
ene phantom. The coronal planes were selected to mea-
sure a combination of boost and elective doses. All
measurements were performed for the combination of
the two arcs and they were compared to the calculated
dose of the same patient plan on the CT-scan with the
respective phantom. A gamma-evaluation was per-
formed, using dose differences of 3% and distance to
agreement of 2 mm.
Routine patient set-up was performed using two
orthogonal kV-images (OBI, Varian Medical Systems)
performed prior to each of the first 3 fractions, which
were registered to digitally computed radiographs from
the planning CT-scan using translations only. After the
fourth fraction, patients were positioned according to
the mean of the first 3 set-ups. The set-up procedure
was repeated after 20 fractions, and a cone beam
CTscan (CBCT) was then performed to ensure PTV
coverage.
Toxicity and quality of life assessment
Patients are all included in a standardized follow-up
program with weekly evaluation by the radiation oncolo-
gist and scoring of toxicity according to the RTOG
Radiation Morbidity Scoring Criteria [27]. Health-related
QoL was routinely assessed using the EORTC QLQ-C30
and H&N35 questionnaires at baseline, 1 and 6 months
post treatment and at 6-month intervals thereafter
[28,29].
Results
All 31 patients completed CLSM sparing radiotherapy as
was planned. Median follow up was 19 months (range
14-25 months). To date, no regional recurrences have
been observed. Two patients developed a local recur-
rence and underwent a total laryngectomy. Two patients
had a local recurrence with lung metastases. One patient
developed lung metastases only.
Target coverage
The mean volumes of PTVelect and PTVboost (588 cm
3
and 178 cm3, respectively) for patients in group 1 were
similar to that in group 2 (565 cm3 and 118 cm3). Mean
PTV coverage, CI and OAR doses for both the sparing
and the non-sparing plans, are summarised in Table 3.
The PTV coverage of all 31 patients studied was excel-
lent, with on average 98.7% of PTVelect and 99.2% of
PTVboost receiving ≥ 95% of the prescription dose. In
‘non-sparing’ plans, the corresponding PTV coverage
was 98.9% and 99.2%, respectively. For both plans, on
average, only 0.8% of PTVboost received >107%. The
resulting plan CI was 1.18 in group 1, and 1.14 in group
2 (not different from the CI ‘non-sparing’ plans).
Sparing of the CLSM gland did not significantly reduce
the volume encompassed by the 95% isodoseline of the
elective or boost doses compared to the non-sparing
plans (Wilcoxon signed-ranks test p = 0.16 and p = 0.64
respectively). An example of the clinical and non-sparing
plan in a typical patient can be appreciated in Figure 1.
Organs at risk (OAR)
With the exception of the mean dose in the CLSM
gland, no differences in doses to other OARs were
observed for clinical and non-sparing plans. In group 1,
the mean CLSM gland dose was 33.2 Gy (clinical plans)
and 50.6 Gy (non-sparing) (p < 0.001). The maximum
dose to the spinal canal was on average 40.2 Gy (com-
pared to 40 Gy in the non-sparing plans). IL and CL
parotids received 32.1 Gy and 21.9 Gy respectively (ver-
sus 31.5 Gy and 21.5 Gy in the non-sparing plans).
In group 2, the mean CLSM gland dose was 34.4 Gy
for clinical plans, and 46.8 Gy for non-sparing plans (p
0.002). The maximum dose to the spinal canal was 38.6
Gy (as opposed to 38.3 Gy in the non-sparing plans).
Clinical IL and CL parotid doses were 25.7 Gy and 19.6
Gy respectively, versus 25.8 Gy and 19.6 Gy in non-
sparing plans.
In the follow up cohort of 25 patients treated using
the same technique, the mean CLSM dose was 32.8 Gy.
Both PTVelect and PTVboost coverage was again excel-
lent, with 98.4% and 99.3% of volumes receiving 95% of
the prescription dose.
Acute toxicity
Acute toxicity observed was consistent with the toxicity
seen in patients treated with conventional IMRT deliv-
ery to these doses [6]. In group 1 (21 patients), 5
patients experienced RTOG grade 3 cutaneous toxicity
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(moist desquamation). Half (10) of all patients had a
confluent mucositis (RTOG grade 3 toxicity) and 19
patients required opioid analgesia. Fifteen patients devel-
oped grade 2 xerostomia with markedly altered taste.
Prophylactic placement of a percutaneous endoscopic
gastrostomy tube (PEG-tube) was performed in 19
patients, and all but one patient actually used the PEG-
tube.
Table 3 Results
Site SM CL SM CL
(non-
sparing)
PG IL PG IL
(non-
sparing)
PG CL PG CL
(non-
sparing)
Sp C Sp C
(non-
sparing)
V B ≥95% V E ≥95%
A mean 33.7 51.5 34.2 33.3 21.8 21.4 42.1 41.9 99.3 98.9
range (46.5-57.3) (24.7-41.6) (16.6-54.3) (16.3-53.2) (12.2-31.8) 14.2-32.1) (37-50) (35.8-49) (98.9-99.9) (98.2-99.5)
B mean 32.4 49 27.9 27.8 22 21.9 36.4 36.3 99.7 98.5
range (44.3-52.8) (29.7-39.5) (16.4-55.5) (16-55.7) (16.7-30.6) (16.7-30.3) (23-49.8) (23-49.8) (99-99.9) (97.9-98.9)
C mean 35.1 47.1 28.7 29.1 21.9 22 40 39.8 98.5* 98.9
range (43.7-52.4) (26.6-40.6) (16.5-48.2) (17-46.3) (13.6-30.9) (14.5-30.7) (30-44.9) (29.7-45.3) (96.2-99.6) (97.9-98.9)
D mean 33.4 46.4 21.2 21 16.2 16 36.4 36 99.6 98.3
range (42.2-51.8) (30-36.8) (12.7-35.7) (12.4-35.6) (10.7-26.1) (10.3-26.3) (24.7-41) (24.4-41.2) (99.1-99.9) (97.6-98.9)
A: oropharynx, elective dose 57.75 Gy (14 patients) Doses in Gy
B: larynx/hypopharynx, elective dose 57.75 Gy (7 patients) Sp C: spinal cord
C: oropharynx, elective dose 54.25 Gy (6 patients)
D: larynx/hypopharynx, elective dose 54.25 Gy (4 patients)
V B ≥95%:% of PTV boost receiving ≥95% of the prescribed dose
V E ≥95%:% of PTV elective receiving ≥95% of the prescribed dose
*: in 1 patient with T1 carcinoma of the soft palate, 96.2% of PTVboost received 95% of prescribed dose, this was accepted because of the fact that a large part of
the PTVboost consisted of air.
Figure 1 Dose distributions and DVH for a typical patient with an oropharyngeal tumor. Comparison of clinical plan (pictures right) with
‘non-sparing’ plan (pictures left). PTV in magenta, PTV in blue. DVH (■ = clinical plan, ▲ = ‘non-sparing’ plan) of CLSM in yellow, both PTVs in
red, left PG in purple, right PG in orange, spinal cord in blue.
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In group 2 (10 patients), 7 patients developed conflu-
ent mucositis, and 9 patients experienced a markedly
altered taste our dry mouth (xerostomia grade 2). No
preventive PEG tubes were placed. Only one patient
needed a nasogastric tube. Eight patients required
opioids.
Quality assurance
Film and MatriXx measurements showed that on aver-
age only 1.3% of the measurement points exceeded a
combination of dose difference > 3% or distance to
agreement > 2 mm (range 0-4.6%). For only 6 of the
patients, more than 3% of the measured points exceeded
this limit.
Discussion
The pathogenesis of xerostomia is complex and appears
to depend on not only PG function, as a discrepancy
was noted between preserved PG function measured
using objective tools, and subjective patient-reported
xerostomia [30-33]. As particularly the mucinous secre-
tions of the SM gland contribute to the subjective feel-
ing of oral hydration, we developed and clinically
implemented a technique to spare both the PGs and
CLSM gland in patients undergoing elective irradiation
to clinically negative CL level II-IV nodes. Our main
findings are that reductions in mean dose to the CLSM
gland to 33.2 Gy and 34.4 Gy, respectively, is possible in
who need to undergo elective doses of 57.75 Gy and
54.25 Gy.
SM glands are located adjacent to the jugulodigastric
nodes, which are the first echelon for most HNC tumors.
Consequently, SM sparing is infrequently considered for
fear of reducing PTV coverage [2]. We observed no com-
promise in PTV coverage in most patients, although 5
clinical plans had a minor underdosage (to 90% of the
prescribed elective dose) in 0.5 cm3 to the PTVelect in the
vicinity of the CLSM. In all these 5 patients, the coverage
of the PTVelect met our clinical acceptance criteria as
97.9% - 98.6% was covered by 95% of the elective dose.
For the purposes of the current study, plans for all these
5 patients were repeated using a PTVelect margin of 5
mm (3 mm standard + 2 mm extra) for the PTV regions
directly adjacent to the CLSM gland. In all patients, the
volume of underdosage could be reduced to 0-0.2 cm3. In
2 patients, the mean CLSM dose remained the same, in 2
patients there was an increase of 1.6 Gy and in 1 patient
an increase from 31.8 to 35.7 Gy. Consequently, we cur-
rently enlarge the PTVelect adjacent to CLSM with an
extra 2 mm in order to reduce the likelihood of creating
a small rim of underdosage in the PTVelect. It is reassur-
ing to note the application of our technique in an addi-
tional 25 patients revealed that the reduction in CLSM
doses was maintained.
With a short median follow up in our 31 patients of
19 months, no contralateral regional recurrences were
observed. Recent work in 285 patients indicates that iso-
lated regional relapse in the elective contralateral neck
are very uncommon after the use of IMRT [34]. These
authors delivered a dose of 56 Gy in 32 fractions to
elective regions, which was comparable to the doses
used in our patients. As we found no significant differ-
ences between the clinical and the non-sparing plans in
PTV receiving at least 95% of the elective and boost
doses, the likelihood of recurrences in the vicinity of the
CLSM are expected to be low.
Few studies have addressed the dose-response rela-
tionships of the SM gland. A study measuring unstimu-
lated whole mouth salivary flow suggested a TD50 of
32.6 Gy at 6 months and 34.1 Gy at 12 months for the
SM gland [35]. A study in 148 patients treated with
IMRT, where no attempt was made to spare the SM
glands, resulted in only a limited number of data points
in the low-dose region of the SM [36]. Data from this
study suggested an exponential mean dose-related
decrease in SM output, up to a threshold of 39 Gy,
above which little or no recovery of salivary flow was
seen.
Other approaches for sparing the SM gland have been
reported. A planning study in 10 patients with orophar-
yngeal cancer which delivered a dose of 54 Gy to the
CL PTVelect, reported a reduction in mean CLSM gland
dose from 54 Gy to 40 Gy [37] However, these authors
had to accept an underdosage in the vicinity of the CL
PTVelect to 90% of the prescribed dose. Surgical transfer
of the SM gland into the submental space outside the
field can lead to a significant improvement of salivary
function [16]. The same authors recently performed a
planning study combining SM gland transfer with helical
tomotherapy in patients undergoing postoperative RT,
and reported achieving a mean dose of 23 Gy in the
spared SM gland [38]. In a study where 18 patients
actually underwent treatment using plans to limit mean
CLSM gland dose to below 26 Gy, no clear definition of
the doses in CTVs and PTVs was described [35]. In this
study, an underdosage in PTV of up to 10% at the per-
iphery of the CLSM gland was accepted and volumes of
underdosage were not reported [39]. Another study
recently reported on CLSM sparing in mostly postopera-
tive patients, who comprised 47 of the 52 cases [17]. An
impressive reduction in the mean dose to the CLSM
gland from 57.4 Gy (non-spared group) to 20.4 Gy
(spared group) was described. However, a coverage of
95% of the PTV was considered acceptable and no data
on regions of potential underdosage were described.
The lower mean CLSM gland dose resulted into a lower
RTOG xerostomia score and stimulatated slivary flow
rates up to 6 months after therapy (but not thereafter).
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The authors reported that unstimulated salivary flow
rates were significantly better at all time points.
A limitation of our study is the lack of objective
assessment of the SM salivary flow, although it must be
recognized that the assessment of xerostomia can be
subjective and that objective salivary flow measurements
may not translate into patient-reported complaints
[12,14,30,33]. Since a mean dose of less than 35 Gy to
the CLSM gland was achieved, we hope to demonstrate
a significant further decrease in patient-scored xerosto-
mia with longer follow-up.
Conclusion
In HNC patients with a clinically negative contralateral
neck, requiring elective RT to the CL nodal levels II-IV,
use of RapidArc significantly reduced mean doses to the
CLSM gland to below 35 Gy, without compromising
PTV coverage. Longer follow-up is required to exclude
the potential risk of tumor recurrences in the contralat-
eral neck and to demonstrate a significant decrease in
xerostomia.
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